Online citations, reference lists, and bibliographies.
← Back to Search

PH-Responsive PEG-Shedding And Targeting Peptide-Modified Nanoparticles For Dual-Delivery Of Irinotecan And MicroRNA To Enhance Tumor-Specific Therapy.

V. Juang, Chih-Hsien Chang, Chen-Shen Wang, Hsin-Ell Wang, Yu-Li Lo
Published 2019 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Irinotecan is one of the main chemotherapeutic agents for colorectal cancer (CRC). MicroRNA-200 (miR-200) has been reported to inhibit metastasis in cancer cells. Herein, pH-sensitive and peptide-modified liposomes and solid lipid nanoparticles (SLN) are designed for encapsulation of irinotecan and miR-200, respectively. These peptides include one cell-penetrating peptide, one ligand targeted to tumor neovasculature undergoing angiogenesis, and one mitochondria-targeting peptide. The peptide-modified nanoparticles are further coated with a pH-sensitive PEG-lipid derivative with an imine bond. These specially-designed nanoparticles exhibit pH-responsive release, internalization, and intracellular distribution in acidic pH of colon cancer HCT116 cells. These nanoparticles display low toxicity to blood and noncancerous intestinal cells. Delivery of miR-200 by SLN further increases the cytotoxicity of irinotecan-loaded liposomes against CRC cells by triggering apoptosis and suppressing RAS/β-catenin/ZEB/multiple drug resistance (MDR) pathways. Using CRC-bearing mice, the in vivo results further indicate that irinotecan and miR-200 in pH-responsive targeting nanoparticles exhibit positive therapeutic outcomes by inhibiting colorectal tumor growth and reducing systemic toxicity. Overall, successful delivery of miR and chemotherapy by multifunctional nanoparticles may modulate β-catenin/MDR/apoptosis/metastasis signaling pathways and induce programmed cancer cell death. Thus, these pH-responsive targeting nanoparticles may provide a potential regimen for effective treatment of colorectal cancer.
This paper references
10.1016/j.biomaterials.2013.12.094
Cell-selective intracellular drug delivery using doxorubicin and α-helical peptides conjugated to gold nanoparticles.
Hyejin Park (2014)
NG2 proteoglycan-binding peptides target tumor neovasculature.
M. Burg (1999)
10.1158/0008-5472.CAN-08-2819
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Thiruvengadam Arumugam (2009)
10.4161/rna.5.3.6558
The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis
M. Korpal (2008)
10.1371/journal.pone.0082478
Galectin-3 Silencing Inhibits Epirubicin-Induced ATP Binding Cassette Transporters and Activates the Mitochondrial Apoptosis Pathway via β-Catenin/GSK-3β Modulation in Colorectal Carcinoma
Yung-Kuo Lee (2013)
10.1245/s10434-014-4217-1
A Cancer Reprogramming Method Using MicroRNAs as a Novel Therapeutic Approach against Colon Cancer
S. Miyazaki (2014)
10.1002/smll.201900631
Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
Yuanyuan Pei (2019)
10.18632/oncotarget.6725
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
Caroline Brand (2016)
10.3109/10717544.2015.1040527
Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma
M. Yuan (2016)
10.3892/ijmm.2016.2689
Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family
M. A. Suliman (2016)
10.1016/j.biomaterials.2015.02.004
Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
L. Jiang (2015)
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
X. Chu (1999)
10.1016/j.bmc.2013.02.030
Systematic screening of the cellular uptake of designed alpha-helix peptides.
K. Usui (2013)
10.1038/nrc706
Multidrug resistance in cancer: role of ATP–dependent transporters
M. Gottesman (2002)
10.1016/j.biomaterials.2013.12.027
Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Ying-Yun Guan (2014)
10.1093/ANNONC/MDF337
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Y. Xu (2002)
10.1248/bpb.b14-00695
Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
S. Tanaka (2015)
10.1021/nl0805615
Method for analysis of nanoparticle hemolytic properties in vitro.
M. Dobrovolskaia (2008)
10.1016/S0959-4388(00)00097-0
Sequential steps in clathrin-mediated synaptic vesicle endocytosis
L. Brodin (2000)
10.3390/ijms17121998
Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
Kuan-Hung Lin (2016)
10.1016/j.bmc.2017.04.025
Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Y. Du (2017)
10.1016/j.biomaterials.2014.03.046
pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.
Yi-Ting Chiang (2014)
10.1007/s13277-016-4961-x
iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice
Wang Qi-fan (2016)
10.1016/j.ejca.2015.04.021
Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer.
N. Ghahhari (2015)
10.1016/j.colsurfb.2014.09.061
Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
L. Negi (2014)
10.3389/fnagi.2016.00068
Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson’s Disease
Wei Chen (2016)
10.1371/journal.pone.0036490
MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors
M. Lerner (2012)
10.1007/s00109-016-1420-5
miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance
Merve Mutlu (2016)
10.3892/MCO.2015.577
Angiopoietin-like protein 2 as a potential biomarker for colorectal cancer.
Takuma Yoshinaga (2015)
10.1016/j.taap.2013.12.018
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
E. Filipski (2014)
10.1016/j.ijbiomac.2014.09.005
Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma.
L. Negi (2015)
10.18632/ONCOTARGET.3052
The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy
Brock A Humphries (2015)
10.18632/oncotarget.8518
Adipogenic miRNA and meta-signature miRNAs involved in human adipocyte differentiation and obesity
Chunmei Shi (2016)
10.1016/j.jconrel.2013.11.020
Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery.
Feihu Wang (2014)
10.7150/thno.25625
Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease
Ta-Chung Liu (2018)
10.1158/1535-7163.MCT-05-0509
A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity
Benedict Law (2006)
10.18632/oncotarget.8719
Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting
J. Kim (2016)
10.1002/JPS.20627
In vitro hemolysis: guidance for the pharmaceutical scientist.
K. Amin (2006)
10.1158/0008-5472.CAN-04-2488
Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL
Rajani Ravi (2004)
10.1248/BPB.30.1400
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Y. Takeba (2007)
10.1038/srep28465
pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates
Kelly E. Burns (2016)
10.1007/s00441-015-2141-8
Proteoglycans as potential microenvironmental biomarkers for colon cancer
A. V. Suhovskih (2015)



This paper is referenced by
10.3892/ol.2019.11246
MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma
Maoyuan Li (2020)
10.7150/thno.45164
PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer
Yu-Li Lo (2020)
10.3390/ijms21072536
Nanoparticles Modified with Cell-Penetrating Peptides: Conjugation Mechanisms, Physicochemical Properties, and Application in Cancer Diagnosis and Therapy
Isabel Gessner (2020)
10.3390/molecules25204701
Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals
S. Son (2020)
10.1002/biot.201900408
Smart Nanocarriers for the Delivery of Nucleic Acid-based Therapeutics: A Comprehensive Review.
T. Ramasamy (2020)
10.3389/fbioe.2020.00166
Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials
Riccardo Rampado (2020)
10.1039/d0tb00649a
Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy.
Y. Zhou (2020)
10.3390/pharmaceutics12080756
Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics
Yu-Li Lo (2020)
10.3390/ijms21186961
Self-Assembly of Amphiphilic Compounds as a Versatile Tool for Construction of Nanoscale Drug Carriers
R. Kashapov (2020)
10.3390/nano10071424
Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy
Chunhua Yang (2020)
10.1208/s12249-020-01731-y
Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents
L. Cabeza (2020)
10.1016/j.jconrel.2020.09.055
Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment.
Jafrin Jobayer Sonju (2020)
10.1080/14712598.2021.1823368
Status Update in the Use of Cell Penetrating Peptides for the Delivery of Macromolecular Therapeutics.
K. Kurrikoff (2020)
Semantic Scholar Logo Some data provided by SemanticScholar